Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability - Positive endometrial cancer

Takashi Iwata, Tomonobu Fujita, Nobumaru Hirao, Yuriko Matsuzaki, Tsutomu Okada, Hiroshi Mochimaru, Nobuyuki Susumu, Eri Matsumoto, Kokichi Sugano, Naohide Yamashita, Shiro Nozawa, Yutaka Kawakami

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Identification of cancer/testis antigens useful for diagnosis or immunotherapy of cancers was attempted by cDNA expression cloning with patients' sera (SEREX). Experimental Design: cDNA expression libraries made from testis or endometrial cancer cell lines were screened using sera from patients with endometrial cancer or melanoma patients immunized with dendritic cells pulsed with autologous tumor lysates. Tissue-specific expression by RT-PCR and immunogenicity by Western blotting of the bacterial recombinant antigen with sera from cancer patients were evaluated. Results: A cancer/testis antigen, CAGE, was isolated by two independently performed SEREX. CAGE was expressed in various cancer cell lines including endometrial cancer, colon cancer, and melanoma in 7 of 10 endometrial cancer tissues and in 1 of 3 atypical endometrial hyperplasia, but not in normal tissues including the endometrium and testis. The protein expression on cancer cells was confirmed by Western blot analysis with the recombinant CAGE protein, anti-CAGE IgG antibody was detected in sera from 5 of 45 endometrial cancer, 2 of 24 melanoma, and 2 of 33 colon cancer patients, but not in sera from healthy individuals. By ELISA analysis, anti-CAGE antibody was detected in 12 of 45 endometrial cancer, 2 of 20 melanoma, and 4 of 33 colon cancer patients. Intriguingly, anti-CAGE antibody was highly positive in 7 of the 13 (53.8%) microsatellite instability (MSI)-H patients with endometrial cancer, but negative in 20 non-MSI-H patients (P = 0.001). Conclusion: CAGE may be useful for immunotherapy and diagnosis of various cancers particularly MSI-positive endometrial cancer.

Original languageEnglish
Pages (from-to)3949-3957
Number of pages9
JournalClinical Cancer Research
Volume11
Issue number10
DOIs
Publication statusPublished - 2005 May 15

Fingerprint

Microsatellite Instability
Testicular Neoplasms
Endometrial Neoplasms
Antigens
Colonic Neoplasms
Melanoma
Neoplasms
Serum
Immunotherapy
Anti-Idiotypic Antibodies
Western Blotting
Bacterial Antigens
Endometrial Hyperplasia
Cell Line
Endometrium
Gene Library
Recombinant Proteins
Dendritic Cells
Testis
Organism Cloning

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability - Positive endometrial cancer. / Iwata, Takashi; Fujita, Tomonobu; Hirao, Nobumaru; Matsuzaki, Yuriko; Okada, Tsutomu; Mochimaru, Hiroshi; Susumu, Nobuyuki; Matsumoto, Eri; Sugano, Kokichi; Yamashita, Naohide; Nozawa, Shiro; Kawakami, Yutaka.

In: Clinical Cancer Research, Vol. 11, No. 10, 15.05.2005, p. 3949-3957.

Research output: Contribution to journalArticle

Iwata, T, Fujita, T, Hirao, N, Matsuzaki, Y, Okada, T, Mochimaru, H, Susumu, N, Matsumoto, E, Sugano, K, Yamashita, N, Nozawa, S & Kawakami, Y 2005, 'Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability - Positive endometrial cancer', Clinical Cancer Research, vol. 11, no. 10, pp. 3949-3957. https://doi.org/10.1158/1078-0432.CCR-04-1702
Iwata, Takashi ; Fujita, Tomonobu ; Hirao, Nobumaru ; Matsuzaki, Yuriko ; Okada, Tsutomu ; Mochimaru, Hiroshi ; Susumu, Nobuyuki ; Matsumoto, Eri ; Sugano, Kokichi ; Yamashita, Naohide ; Nozawa, Shiro ; Kawakami, Yutaka. / Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability - Positive endometrial cancer. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 10. pp. 3949-3957.
@article{746f7a6a773d48f2bc21d75e9fe9b480,
title = "Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability - Positive endometrial cancer",
abstract = "Purpose: Identification of cancer/testis antigens useful for diagnosis or immunotherapy of cancers was attempted by cDNA expression cloning with patients' sera (SEREX). Experimental Design: cDNA expression libraries made from testis or endometrial cancer cell lines were screened using sera from patients with endometrial cancer or melanoma patients immunized with dendritic cells pulsed with autologous tumor lysates. Tissue-specific expression by RT-PCR and immunogenicity by Western blotting of the bacterial recombinant antigen with sera from cancer patients were evaluated. Results: A cancer/testis antigen, CAGE, was isolated by two independently performed SEREX. CAGE was expressed in various cancer cell lines including endometrial cancer, colon cancer, and melanoma in 7 of 10 endometrial cancer tissues and in 1 of 3 atypical endometrial hyperplasia, but not in normal tissues including the endometrium and testis. The protein expression on cancer cells was confirmed by Western blot analysis with the recombinant CAGE protein, anti-CAGE IgG antibody was detected in sera from 5 of 45 endometrial cancer, 2 of 24 melanoma, and 2 of 33 colon cancer patients, but not in sera from healthy individuals. By ELISA analysis, anti-CAGE antibody was detected in 12 of 45 endometrial cancer, 2 of 20 melanoma, and 4 of 33 colon cancer patients. Intriguingly, anti-CAGE antibody was highly positive in 7 of the 13 (53.8{\%}) microsatellite instability (MSI)-H patients with endometrial cancer, but negative in 20 non-MSI-H patients (P = 0.001). Conclusion: CAGE may be useful for immunotherapy and diagnosis of various cancers particularly MSI-positive endometrial cancer.",
author = "Takashi Iwata and Tomonobu Fujita and Nobumaru Hirao and Yuriko Matsuzaki and Tsutomu Okada and Hiroshi Mochimaru and Nobuyuki Susumu and Eri Matsumoto and Kokichi Sugano and Naohide Yamashita and Shiro Nozawa and Yutaka Kawakami",
year = "2005",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1702",
language = "English",
volume = "11",
pages = "3949--3957",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability - Positive endometrial cancer

AU - Iwata, Takashi

AU - Fujita, Tomonobu

AU - Hirao, Nobumaru

AU - Matsuzaki, Yuriko

AU - Okada, Tsutomu

AU - Mochimaru, Hiroshi

AU - Susumu, Nobuyuki

AU - Matsumoto, Eri

AU - Sugano, Kokichi

AU - Yamashita, Naohide

AU - Nozawa, Shiro

AU - Kawakami, Yutaka

PY - 2005/5/15

Y1 - 2005/5/15

N2 - Purpose: Identification of cancer/testis antigens useful for diagnosis or immunotherapy of cancers was attempted by cDNA expression cloning with patients' sera (SEREX). Experimental Design: cDNA expression libraries made from testis or endometrial cancer cell lines were screened using sera from patients with endometrial cancer or melanoma patients immunized with dendritic cells pulsed with autologous tumor lysates. Tissue-specific expression by RT-PCR and immunogenicity by Western blotting of the bacterial recombinant antigen with sera from cancer patients were evaluated. Results: A cancer/testis antigen, CAGE, was isolated by two independently performed SEREX. CAGE was expressed in various cancer cell lines including endometrial cancer, colon cancer, and melanoma in 7 of 10 endometrial cancer tissues and in 1 of 3 atypical endometrial hyperplasia, but not in normal tissues including the endometrium and testis. The protein expression on cancer cells was confirmed by Western blot analysis with the recombinant CAGE protein, anti-CAGE IgG antibody was detected in sera from 5 of 45 endometrial cancer, 2 of 24 melanoma, and 2 of 33 colon cancer patients, but not in sera from healthy individuals. By ELISA analysis, anti-CAGE antibody was detected in 12 of 45 endometrial cancer, 2 of 20 melanoma, and 4 of 33 colon cancer patients. Intriguingly, anti-CAGE antibody was highly positive in 7 of the 13 (53.8%) microsatellite instability (MSI)-H patients with endometrial cancer, but negative in 20 non-MSI-H patients (P = 0.001). Conclusion: CAGE may be useful for immunotherapy and diagnosis of various cancers particularly MSI-positive endometrial cancer.

AB - Purpose: Identification of cancer/testis antigens useful for diagnosis or immunotherapy of cancers was attempted by cDNA expression cloning with patients' sera (SEREX). Experimental Design: cDNA expression libraries made from testis or endometrial cancer cell lines were screened using sera from patients with endometrial cancer or melanoma patients immunized with dendritic cells pulsed with autologous tumor lysates. Tissue-specific expression by RT-PCR and immunogenicity by Western blotting of the bacterial recombinant antigen with sera from cancer patients were evaluated. Results: A cancer/testis antigen, CAGE, was isolated by two independently performed SEREX. CAGE was expressed in various cancer cell lines including endometrial cancer, colon cancer, and melanoma in 7 of 10 endometrial cancer tissues and in 1 of 3 atypical endometrial hyperplasia, but not in normal tissues including the endometrium and testis. The protein expression on cancer cells was confirmed by Western blot analysis with the recombinant CAGE protein, anti-CAGE IgG antibody was detected in sera from 5 of 45 endometrial cancer, 2 of 24 melanoma, and 2 of 33 colon cancer patients, but not in sera from healthy individuals. By ELISA analysis, anti-CAGE antibody was detected in 12 of 45 endometrial cancer, 2 of 20 melanoma, and 4 of 33 colon cancer patients. Intriguingly, anti-CAGE antibody was highly positive in 7 of the 13 (53.8%) microsatellite instability (MSI)-H patients with endometrial cancer, but negative in 20 non-MSI-H patients (P = 0.001). Conclusion: CAGE may be useful for immunotherapy and diagnosis of various cancers particularly MSI-positive endometrial cancer.

UR - http://www.scopus.com/inward/record.url?scp=21044433417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044433417&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1702

DO - 10.1158/1078-0432.CCR-04-1702

M3 - Article

VL - 11

SP - 3949

EP - 3957

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -